ClinicalTrials.gg
CompletedNCT03989206Updated Oct 20, 2026

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

A Phase 3 interventional study of Nemolizumab in Moderate-to-Severe Atopic Dermatitis, sponsored by Galderma R&D. Completed at 343 sites in 22 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

Updated Oct 20, 2026Now CompletedEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,935
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing nemolizumab in Dermatitis, Atopic — 3 open to participants now, 3 under way, 1 of them phase 3. nemolizumab · Dermatitis, Atopic.

Enrollment
Largest of 14
1,935 · median 209
Started
2019
with 3 others
Phase 3
5 of 14
1 open now
Registered
5th of 14
by date
Lead sponsor
12 of 14
Galderma R&D

Among the 14 studies testing nemolizumab in Dermatitis, Atopic, this one has the largest enrollment, is one of 4 that started in 2019, is one of 5 in phase 3, and was the 5th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

3 of the 14 studies testing nemolizumab in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nemolizumab

nemolizumab: first FDA approval 2024 (NEMLUVIO), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing nemolizumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Read the detailed description

Long-term study to assess the safety and efficacy of nemolizumab in subjects with moderate-to-severe AD

03

Conditions studied

  • Moderate-to-Severe Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Subjects who may benefit from study participation in the opinion of the investigator and had participated in a prior nemolizumab study for AD
  2. Female subjects of (ie, fertile, following menarche and until becoming unless permanently sterile) must agree either to be strictly abstinent throughout the study and for 12 weeks after the last study drug injection, or to use an effective and approved method of throughout the study and for 12 weeks after the last study drug injection.

Key Exclusion Criteria:

  1. Subjects who, during their participation in a prior nemolizumab study, experienced an AE which in the opinion of the investigator could indicate that continued treatment with nemolizumab may present an unreasonable risk for the subject.
  2. Pregnant women, breastfeeding women, or women planning a pregnancy during the clinical study.
  3. Body weight \< 30 kg
  4. Cutaneous infection within 1 week before the baseline visit, any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics or antifungals within 2 weeks before the baseline visit, or any confirmed or suspected coronavirus disease (COVID)-19 infection within 2 weeks before the screening or baseline visit. Subjects may be rescreened once the infection has resolved. Resolution of COVID-19 infection can be confirmed by recovery assessment methods.
  5. History of (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, eg, monoclonal antibody)
  6. Any issue, based investigator judgement
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,935 participants (actual)

Study arms

  • Experimental
    Nemolizumab

    Nemolizumab administered via subcutaneous injection

    Drug: Nemolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and Severity of TEAEs

    Time frame: Baseline to Week 200

  2. Incidence of Serious TEAEs

    Time frame: Baseline to Week 200

  3. Incidence and Severity of Adverse Events of Special Interest (AESIs) Throughout the Study

    Time frame: Baseline to Week 200

Secondary outcomes

  1. Proportion of Participants with IGA score = 0-1 at Each Visit

    Time frame: Baseline to Week 200

  2. Proportion of Participants with EASI-75 at Each Visit

    Time frame: Baseline to Week 200

  3. Change and Percent Change From Baseline in Overall Eczema Area and Severity Index (EASI) Score at Each Visit

    EASI assesses severity and extent of AD signs through a composite score of erythema, induration/population, excoriation, and lichenification. The severity will be assessed on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs, with half points allowed. The EASI score can range from 0 to 72 with higher scores representing greater severity of atopic dermatitis.

    Time frame: Baseline to Week 200

  4. Proportion of Participants with IGA ≤ 2 at Each Visit

    Time frame: Baseline to Week 200

  5. Change and Percent Change From Baseline in SCORAD Score at Each Visit

    Time frame: Baseline to Week 200

  6. Change and Percent Change From Baseline in Participant-Reported Pruritus Using 10-cm VAS (SCORAD Sub-Component)

    Time frame: Baseline to Week 200

  7. Change and Percent Change From Baseline in Participant-Reported Sleep Loss Using 10-cm VAS (SCORAD Sub-Component)

    Time frame: Baseline to Week 200

  8. Proportion of Participants Reporting Low Disease Activity State Based on PGAD at Each Visit

    Time frame: Baseline to Week 200

  9. Proportion of Participants Satisfied with Study Treatment Based on PGAT at each visit

    Time frame: Baseline to Week 200

  10. Change from Baseline in Dermatology Life Quality Index (DLQI)

    Time frame: Baseline to Week 200

  11. Change From Baseline in Children's Dermatology Life Quality Index (cDLQI) Total Score at Each Visit Through Week 200

    Time frame: Baseline to Week 200

  12. Change From Baseline in Patient-Oriented Eczema Measure (POEM) Total Score at Each Visit Through Week 200

    Time frame: Baseline to Week 200

  13. Change From Baseline in Hospital Anxiety and Depression Scale (HADS) for Each Subscale at Each Visit Through Week 200

    Time frame: Baseline to Week 200

  14. Change From Baseline in Work Productivity and Activity Impairment: Atopic Dermatitis (WPAI:AD) for Each Subscale at Each Visit Through Week 200

    Time frame: Baseline to Week 200

  15. Change From Baseline in EuroQoL 5-Dimension (EQ-5D) at Each Visit Through Week 200

    Time frame: Baseline to Week 200

  16. Proportion of Participants Receiving Any Rescue Therapy by Rescue Treatment Type at Any Visit During the Treatment Period

    Time frame: Baseline to Week 200

  17. Time to First Relapse

    Time frame: Baseline to Week 200

  18. Duration of Remission

    Time frame: Baseline to Week 200

  19. Time to Permanent Study Drug Discontinuation

    Time frame: Baseline to Week 200

07

Study locations

343 sites
  • Galderma Investigational Site 8749
    Birmingham, Alabama 35244, United States
  • Galderma Investigational Site 8893
    Birmingham, Alabama 35244, United States
  • Galderma Investigational Site 8866
    Guntersville, Alabama 35976, United States
  • Galderma Investigational Site 8808
    Scottsdale, Arizona 85255, United States
  • Galderma Investigational Site 8873
    Scottsdale, Arizona 85260, United States
  • Galderma Investigational Site 8447
    Fort Smith, Arkansas 72916, United States
  • Galderma Investigational Site 8880
    North Little Rock, Arkansas 72117, United States
  • Galderma Investigational Site 8831
    Anaheim, California 92801, United States
  • Galderma Investigational Site 8906
    Bell Gardens, California 90201, United States
  • Galderma Investigational Site 8456
    Beverly Hills, California 90212, United States
  • Galderma Investigational Site 8578
    Cerritos, California 90703, United States
  • Galderma Investigational Site 8577
    Encinitas, California 92024, United States
  • Galderma Investigational Site 8636
    Fountain Valley, California 92708, United States
  • Galderma Investigational Site 8224
    Fremont, California 94538, United States
  • Galderma Investigational Site 8791
    Fresno, California 93720, United States
  • Galderma Investigational Site 8888
    Fullerton, California 92835, United States
  • Galderma Investigational Site 8845
    Huntington Beach, California 92647, United States
  • Galderma Investigational Site 8833
    Inglewood, California 90301, United States
  • Galderma Investigational Site 8686
    Lomita, California 90717, United States
  • Galderma Investigational Site 8674
    Los Angeles, California 90025, United States
  • Galderma Investigational Site 8683
    Los Angeles, California 90033, United States
  • Galderma Investigational Site 8813
    Los Angeles, California 90057, United States
  • Galderma Investigational Site 8907
    Newport Beach, California 92660, United States
  • Galderma Investigational Site 8799
    Ontario, California 91762, United States
  • Galderma Investigational Site 8745
    Pasadena, California 91105, United States
  • Galderma Investigational Site 8671
    San Diego, California 92108, United States
  • Galderma Investigational Site 8692
    San Diego, California 92121, United States
  • Galderma Investigational Site 8658
    San Diego, California 92123, United States
  • Galderma Investigational Site 8125
    San Francisco, California 94115, United States
  • Galderma Investigational Site 8536
    Santa Ana, California 92705, United States
  • Galderma Investigational Site 8608
    Santa Monica, California 90404, United States
  • Galderma Investigational Site 8820
    Westminster, California 92683, United States
  • Galderma Investigational Site 8637
    Farmington, Connecticut 06606, United States
  • Galderma Investigational Site 8870
    Boca Raton, Florida 33433, United States
  • Galderma Investigational Site 8805
    Cape Coral, Florida 33991, United States
  • Galderma Investigational Site 8786
    Clearwater, Florida 33765, United States
  • Galderma Investigational Site 8902
    Doral, Florida 33122, United States
  • Galderma Investigational Site 8391
    Hialeah, Florida 33016, United States
  • Galderma Investigational Site 8804
    Hialeah, Florida 33016, United States
  • Galderma Investigational Site 8711
    Jacksonville, Florida 32256, United States
  • Galderma Investigational Site 8836
    Jacksonville, Florida 32256, United States
  • Galderma Investigational Site 8523
    Largo, Florida 33770, United States
  • Galderma Investigational Site 8850
    Margate, Florida 33063, United States
  • Galderma Investigational Site 8719
    Miami, Florida 33125, United States
  • Galderma Investigational Site 8851
    Miami, Florida 33135, United States
  • Galderma Investigational Site 8656
    Miami, Florida 33137, United States
  • Galderma Investigational Site 8801
    Miami, Florida 33145, United States
  • Galderma Investigational Site 8704
    Miami, Florida 33155, United States
  • Galderma Investigational Site 8737
    Miami, Florida 33174, United States
  • Galderma Investigational Site 8706
    Miami, Florida 33175, United States
  • Galderma Investigational Site 8708
    Miami, Florida 33176, United States
  • Galderma Investigational Site 8806
    Miami Lakes, Florida 33014, United States
  • Galderma Investigational Site 8800
    Miami Lakes, Florida 33016, United States
  • Galderma Investigational Site 8856
    Ormond Beach, Florida 33174, United States
  • Galderma Investigational Site 8734
    Pembroke Pines, Florida 33028, United States
  • Galderma Investigational Site 8203
    Tampa, Florida 33607, United States
  • Galderma Investigational Site 8816
    Tampa, Florida 33613, United States
  • Galderma Investigational Site 8889
    Tampa, Florida 33613, United States
  • Galderma Investigational Site 8839
    Tampa, Florida 33615, United States
  • Galderma Investigational Site 8126
    West Palm Beach, Florida 33401, United States
  • Galderma Investigational Site 8667
    Columbus, Georgia 31904, United States
  • Galderma Investigational Site 8744
    Macon, Georgia 31217, United States
  • Galderma Investigational Site 8728
    Newnan, Georgia 30263, United States
  • Galderma Investigational Site 8707
    Stockbridge, Georgia 30281, United States
  • Galderma Investigational Site 8819
    Nampa, Idaho 83687, United States
  • Galderma Investigational Site 9916
    Chicago, Illinois 60611, United States
  • Galderma Investigational Site 8739
    Normal, Illinois 61761, United States
  • Galderma Investigational Site 8729
    Rolling Meadows, Illinois 60008, United States
  • Galderma Investigational Sites 8571
    Skokie, Illinois 60076, United States
  • Galderma Investigational Site 8712
    Skokie, Illinois 60077, United States
  • Galderma Investigational Site 8142
    Indianapolis, Indiana 46250, United States
  • Galderma Investigational Site 8724
    New Albany, Indiana 47150, United States
  • Galderma Investigational Site 9934
    Shawnee Mission, Kansas 66216, United States
  • Galderma Investigational Site 8771
    Louisville, Kentucky 40241-6162, United States
  • Galderma Investigational Site 8882
    Bangor, Maine 04401, United States
  • Galderma Investigational Site 8743
    Ann Arbor, Michigan 48109, United States
  • Galderma Investigational Site 8512
    Bay City, Michigan 48706, United States
  • Galderma Investigational Site 8554
    Detroit, Michigan 48202, United States
  • Galderma Investigational Site 8617
    Farmington Hills, Michigan 48334, United States
  • Galderma Investigational Site 8155
    Troy, Michigan 48084, United States
  • Galderma Investigational Site 8849
    Troy, Michigan 48084, United States
  • Galderma Investigational Site 8226
    Warren, Michigan 48088, United States
  • Galderma Investigational Site 8748
    Ypsilanti, Michigan 48197, United States
  • Galderma Investigational Site 8521
    Saint Joseph, Missouri 64506, United States
  • Galderma Investigational Site 8718
    Missoula, Montana 59808, United States
  • Galderma Investigational Site 8810
    Omaha, Nebraska 68144, United States
  • Galderma Investigational Site 8740
    Henderson, Nevada 89002, United States
  • Galderma Investigational Site 8825
    Las Vegas, Nevada 89106, United States
  • Galderma Investigational Site 8675
    Las Vegas, Nevada 89119, United States
  • Galderma Investigational Site 8109
    Lebanon, New Hampshire 03766, United States
  • Galderma Investigational Site 8506
    Hackensack, New Jersey 07601, United States
  • Galderma Investigational Site 8826
    Albuquerque, New Mexico 87106, United States
  • Galderma Investigational Site 8242
    Brooklyn, New York 11203, United States
  • Galderma Investigational Site 8741
    Buffalo, New York 14221, United States
  • Galderma Investigational Site 8723
    Cortland, New York 13045, United States
  • Galderma Investigational Site 8828
    Forest Hills, New York 11375, United States
  • Galderma Investigational Site 9925
    Glendale, New York 11385, United States
  • Galderma Investigational Site 8733
    New York, New York 10022, United States
  • Galderma Investigational Site 8620
    New York, New York 10023, United States
  • Galderma Investigational Site 8279
    New York, New York 10075, United States

Showing the first 100 of 343 sites across 22 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Augustin M, Tauber M, Sidbury R, Silverberg JI, Papp KA, Thaci D, De Bruin-Weller MS, Reich A, Peris K, Barber K, Galus R, Kaszuba A, Zirwas M, Nahm WK, Trullenque G, Maintz L, Alpizar S, Son SW, Laquer V, Gold LS, Cheong SY, Ryzhkova A, Drahos A, Ulianov L, Piketty C. Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open-label extension study. J Eur Acad Dermatol Venereol. 2026 May;40(5):841-855. doi: 10.1111/jdv.70080. Epub 2025 Oct 13. PubMed 41081535 ↗
  • Brunner PM. A novel treatment approach for atopic dermatitis. Lancet. 2024 Aug 3;404(10451):407-409. doi: 10.1016/S0140-6736(24)01488-0. Epub 2024 Jul 25. No abstract available. PubMed 39068954 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Aug 2026, 80 months.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 80 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2019
First posted
Jun 18, 2019
StartActual
Dec 30, 2019
Primary completionActual
Aug 31, 2026
CompletionActual
Aug 31, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 20, 2026
Sites
39 sites added, 39 sites removed
Show 39 added (23 Poland, 3 Austria, 3 Czechia, 2 Belgium, 2 South Korea, 2 Spain, 1 Germany, 1 Hungary, 1 Italy, 1 Latvia)
  • Galderma Investigational Site 6194 · Vienna, Austria
  • Galderma Investigational Site 6158 · Vienna, Austria
  • Galderma Investigational Site 6156 · Linz, Austria
  • Galderma Investigational Site 6162 · Liège, Belgium
  • Galderma Investigational Site 6164 · Ghent, Belgium
  • Galderma Investigational Site 6021 · Prague, Czechia
  • Galderma Investigational Site 6054 · Prague, Czechia
  • Galderma Investigational Site 6025 · Prague, Czechia
  • Galderma Investigational Site 6214 · Tübingen, Germany
  • Galderma Investigational Site 6053 · Veszprém, Hungary
  • Galderma Investigational Site 6045 · L’Aquila, Italy
  • Galderma Investigational Site 6113 · Liepāja, Latvia
  • Galderma Investigational Site 5773 · Bialystok, Poland
  • Galderma Investigational Site 6255 · Częstochowa, Poland
  • Galderma Investigational Site 6075 · Gdansk, Poland
  • Galderma Investigational Site 6243 · Gdansk, Poland
  • Galderma Investigational Site 5138 · Gdansk, Poland
  • Galderma Investigational Site 5362 · Krakow, Poland
  • Galderma Investigational Site 6052 · Krakow, Poland
  • Galderma Investigational Site 6245 · Lodz, Poland
  • Galderma Investigational Site 5570 · Lodz, Poland
  • Galderma Investigational Site 5363 · Lodz, Poland
  • Galderma Investigational Site 6231 · Lodz, Poland
  • Galderma Investigational Site 6085 · Poznan, Poland
  • Galderma Investigational Site 6127 · Poznan, Poland
  • Galderma Investigational Site 6048 · Tarnów, Poland
  • Galderma Investigational Site 6065 · Warsaw, Poland
  • Galderma Investigational Site 6122 · Warsaw, Poland
  • Galderma Investigational Site 6242 · Warsaw, Poland
  • Galderma Investigational Site 6064 · Warsaw, Poland
  • …and 9 more on the registry record
Show 39 removed
  • Galderma Investigational Site 6156 · Linz, Austria
  • Galderma Investigational Site 6194 · Vienna, Austria
  • Galderma Investigational Site 6158 · Vienna, Austria
  • Galderma Investigational Site 6164 · Gent, Belgium
  • Galderma Investigational Site 6162 · Liège, Belgium
  • Galderma Investigational Site 6021 · Praha, Czechia
  • Galderma Investigational Site 6054 · Praha, Czechia
  • Galderma Investigational Site 6025 · Praha, Czechia
  • Galderma Investigational Site 6214 · Tuebingen, Germany
  • Galderma Investigational Site 6053 · Veszprem, Hungary
  • Galderma Investigational Site 6045 · L'Aquila, Italy
  • Galderma Investigational Site 6095 · Bucheon-Si, Korea, Republic of
  • Galderma Investigational Site 6154 · Gyeonggi-Do, Korea, Republic of
  • Galderma Investigational Site 6113 · Liepaja, Latvia
  • Galderma Investigational Site 5773 · Białystok, Poland
  • Galderma Investigational Site 6255 · Czestochowa, Poland
  • Galderma Investigational Site 6075 · Gdańsk, Poland
  • Galderma Investigational Site 6243 · Gdańsk, Poland
  • Galderma Investigational Site 5138 · Gdańsk, Poland
  • Galderma Investigational Site 5362 · Kraków, Poland
  • Galderma Investigational Site 6052 · Kraków, Poland
  • Galderma Investigational Site 6085 · Poznań, Poland
  • Galderma Investigational Site 6127 · Poznań, Poland
  • Galderma Investigational Site 6048 · Tarnow, Poland
  • Galderma Investigational Site 6065 · Warszawa, Poland
  • Galderma Investigational Site 6122 · Warszawa, Poland
  • Galderma Investigational Site 6242 · Warszawa, Poland
  • Galderma Investigational Site 6064 · Warszawa, Poland
  • Galderma Investigational Site 6222 · Warszawa, Poland
  • Galderma Investigational Site 6047 · Wrocław, Poland
  • …and 9 more on the registry record
Oct 20, 2026
Enrollment
1700 (estimated)→1935 (actual)
Oct 20, 2026
Publications
2 publications citing this study linked from PubMed, e.g. PubMed 41081535 ↗
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Active, not recruiting→Completed
    Publications 2 publications citing this study linked from PubMed, e.g. PubMed 41081535 ↗
    39 sites added, 39 sites removed
    Show 39 added (23 Poland, 3 Austria, 3 Czechia, 2 Belgium, 2 South Korea, 2 Spain, 1 Germany, 1 Hungary, 1 Italy, 1 Latvia)
    • Galderma Investigational Site 6194 · Vienna, Austria
    • Galderma Investigational Site 6158 · Vienna, Austria
    • Galderma Investigational Site 6156 · Linz, Austria
    • Galderma Investigational Site 6162 · Liège, Belgium
    • Galderma Investigational Site 6164 · Ghent, Belgium
    • Galderma Investigational Site 6021 · Prague, Czechia
    • Galderma Investigational Site 6054 · Prague, Czechia
    • Galderma Investigational Site 6025 · Prague, Czechia
    • Galderma Investigational Site 6214 · Tübingen, Germany
    • Galderma Investigational Site 6053 · Veszprém, Hungary
    • Galderma Investigational Site 6045 · L’Aquila, Italy
    • Galderma Investigational Site 6113 · Liepāja, Latvia
    • Galderma Investigational Site 5773 · Bialystok, Poland
    • Galderma Investigational Site 6255 · Częstochowa, Poland
    • Galderma Investigational Site 6075 · Gdansk, Poland
    • Galderma Investigational Site 6243 · Gdansk, Poland
    • Galderma Investigational Site 5138 · Gdansk, Poland
    • Galderma Investigational Site 5362 · Krakow, Poland
    • Galderma Investigational Site 6052 · Krakow, Poland
    • Galderma Investigational Site 6245 · Lodz, Poland
    • Galderma Investigational Site 5570 · Lodz, Poland
    • Galderma Investigational Site 5363 · Lodz, Poland
    • Galderma Investigational Site 6231 · Lodz, Poland
    • Galderma Investigational Site 6085 · Poznan, Poland
    • Galderma Investigational Site 6127 · Poznan, Poland
    • Galderma Investigational Site 6048 · Tarnów, Poland
    • Galderma Investigational Site 6065 · Warsaw, Poland
    • Galderma Investigational Site 6122 · Warsaw, Poland
    • Galderma Investigational Site 6242 · Warsaw, Poland
    • Galderma Investigational Site 6064 · Warsaw, Poland
    • …and 9 more on the registry record
    Show 39 removed
    • Galderma Investigational Site 6156 · Linz, Austria
    • Galderma Investigational Site 6194 · Vienna, Austria
    • Galderma Investigational Site 6158 · Vienna, Austria
    • Galderma Investigational Site 6164 · Gent, Belgium
    • Galderma Investigational Site 6162 · Liège, Belgium
    • Galderma Investigational Site 6021 · Praha, Czechia
    • Galderma Investigational Site 6054 · Praha, Czechia
    • Galderma Investigational Site 6025 · Praha, Czechia
    • Galderma Investigational Site 6214 · Tuebingen, Germany
    • Galderma Investigational Site 6053 · Veszprem, Hungary
    • Galderma Investigational Site 6045 · L'Aquila, Italy
    • Galderma Investigational Site 6095 · Bucheon-Si, Korea, Republic of
    • Galderma Investigational Site 6154 · Gyeonggi-Do, Korea, Republic of
    • Galderma Investigational Site 6113 · Liepaja, Latvia
    • Galderma Investigational Site 5773 · Białystok, Poland
    • Galderma Investigational Site 6255 · Czestochowa, Poland
    • Galderma Investigational Site 6075 · Gdańsk, Poland
    • Galderma Investigational Site 6243 · Gdańsk, Poland
    • Galderma Investigational Site 5138 · Gdańsk, Poland
    • Galderma Investigational Site 5362 · Kraków, Poland
    • Galderma Investigational Site 6052 · Kraków, Poland
    • Galderma Investigational Site 6085 · Poznań, Poland
    • Galderma Investigational Site 6127 · Poznań, Poland
    • Galderma Investigational Site 6048 · Tarnow, Poland
    • Galderma Investigational Site 6065 · Warszawa, Poland
    • Galderma Investigational Site 6122 · Warszawa, Poland
    • Galderma Investigational Site 6242 · Warszawa, Poland
    • Galderma Investigational Site 6064 · Warszawa, Poland
    • Galderma Investigational Site 6222 · Warszawa, Poland
    • Galderma Investigational Site 6047 · Wrocław, Poland
    • …and 9 more on the registry record
    Enrollment 1700 (estimated)→1935 (actual)
    + 3 other changes: index terms, verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03989206
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Jun 18, 2019
Start date
Dec 30, 2019
Primary completion
Aug 31, 2026
Completion
Aug 31, 2026
Last update
Oct 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nemolizumab

Start the discussion